AML Xenograft Efficiency is Significantly Improved in NOD/SCID-IL2RG Mice Constitutively Expressing Human SCF, GM-CSF and IL-3

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2010 Aug 6

PMID 20686503

Citations 233

Authors

M Wunderlich

F-S Chou

K A Link

B Mizukawa

R L Perry

M Carroll

J C Mulloy

Affiliations

Soon will be listed here.

Citing Articles

Investigating resistance to 5-Azacytidine and Venetoclax in PDX models of MDS/AML.

Basova P, Minarik L, Magalhaes-Novais S, Balounova J, Zemanova Z, Aghova T Front Oncol. 2025; 14():1414950.

PMID: 39839764 PMC: 11747314. DOI: 10.3389/fonc.2024.1414950.

Immune Checkpoint Molecules as Biomarkers of Bone Infection and Clinical Outcome.

Saito M, McDonald K, Grier A, Grier A, Meghwani H, Rangel-Moreno J bioRxiv. 2025; .

PMID: 39803468 PMC: 11722373. DOI: 10.1101/2024.12.30.630837.

Myeloid Cell Mobilization and Recruitment by Human Mesothelioma in NSG-SGM3 Mice.

Shindyapin V, Gubernatorova E, Gorshkova E, Chicherina N, Sysonov F, Yakovleva A Cells. 2025; 13(24.

PMID: 39768223 PMC: 11675005. DOI: 10.3390/cells13242135.

Immune deficiency phenotypes of Il2rg, Rag2 or Il2rg/Rag2 double knockout rats; establishment of human leukemia xenograft models.

Kim J, Lim H, Kwon E, Mashimo T, Kang B Lab Anim Res. 2024; 40(1):43.

PMID: 39731164 PMC: 11673691. DOI: 10.1186/s42826-024-00231-5.

The Crossroads of Clonal Evolution, Differentiation Hierarchy, and Ontogeny in Leukemia Development.

Sturgeon C, Wagenblast E, Izzo F, Papapetrou E Blood Cancer Discov. 2024; 6(2):94-109.

PMID: 39652739 PMC: 11876951. DOI: 10.1158/2643-3230.BCD-24-0235.

References

Nicolini F, Cashman J, Hogge D, Humphries R, Eaves C . NOD/SCID mice engineered to express human IL-3, GM-CSF and Steel factor constitutively mobilize engrafted human progenitors and compromise human stem cell regeneration. Leukemia. 2003; 18(2):341-7. DOI: 10.1038/sj.leu.2403222. View

Mulloy J, Cammenga J, Mackenzie K, Berguido F, Moore M, Nimer S . The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood. 2002; 99(1):15-23. DOI: 10.1182/blood.v99.1.15. View

Shultz L, Ishikawa F, Greiner D . Humanized mice in translational biomedical research. Nat Rev Immunol. 2007; 7(2):118-30. DOI: 10.1038/nri2017. View

Shultz L, Lyons B, Burzenski L, Gott B, Chen X, Chaleff S . Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005; 174(10):6477-89. DOI: 10.4049/jimmunol.174.10.6477. View

Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K . NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood. 2002; 100(9):3175-82. DOI: 10.1182/blood-2001-12-0207. View

Feuring-Buske M, Gerhard B, Cashman J, Humphries R, Eaves C, Hogge D . Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors. Leukemia. 2003; 17(4):760-3. DOI: 10.1038/sj.leu.2402882. View

Wei J, Wunderlich M, Fox C, Alvarez S, Cigudosa J, Wilhelm J . Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell. 2008; 13(6):483-95. PMC: 2486365. DOI: 10.1016/j.ccr.2008.04.020. View

Sanchez P, Perry R, Sarry J, Perl A, Murphy K, Swider C . A robust xenotransplantation model for acute myeloid leukemia. Leukemia. 2009; 23(11):2109-17. PMC: 3659827. DOI: 10.1038/leu.2009.143. View

Mulloy J, Cammenga J, Berguido F, Wu K, Zhou P, Comenzo R . Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. Blood. 2003; 102(13):4369-76. DOI: 10.1182/blood-2003-05-1762. View

10.

Wunderlich M, Krejci O, Wei J, Mulloy J . Human CD34+ cells expressing the inv(16) fusion protein exhibit a myelomonocytic phenotype with greatly enhanced proliferative ability. Blood. 2006; 108(5):1690-7. PMC: 1586104. DOI: 10.1182/blood-2005-12-012773. View